5/7/2024

Ambrisentan Tablets

Products Affected - Description

- Ambrisentan oral tablet, Cipla USA, 10 mg, bottle, 30 count, NDC 69097-0387-02
- Ambrisentan oral tablet, Teva, 10 mg, bottle, 30 count, NDC 00591-2406-30
- Ambrisentan oral tablet, Zydus, 10 mg, bottle, 30 count, NDC 70710-1180-03
- Ambrisentan oral tablet, Zydus, 5 mg, bottle, 30 count, NDC 70710-1179-03

Reason for the Shortage

- Apotex has ambrisentan tablets available.
- Cipla did not provide a reason for the shortage.
- Mylan has ambrisentan tablets available.
- Sun Pharma has ambrisentan tablets available.
- Teva did not provide a reason for the shortage.
- Zydus did not provide a reason for the shortage.
- Gilead has Letairis tablets available.

Available Products

- Letairis oral tablet, Gilead, 10 mg, bottle, 10 count, NDC 61958-0802-05
- Letairis oral tablet, Gilead, 10 mg, bottle, 30 count, NDC 61958-0802-01
- Letairis oral tablet, Gilead, 5 mg, bottle, 10 count, NDC 61958-0801-05
- Letairis oral tablet, Gilead, 5 mg, bottle, 30 count, NDC 61958-0801-01
- Ambrisentan oral tablet, Apotex, 10 mg, bottle, 30 count, NDC 60505-4553-03
- Ambrisentan oral tablet, Apotex, 5 mg, bottle, 30 count, NDC 60505-4552-03
- Ambrisentan oral tablet, Cipla USA, 5 mg, bottle, 30 count, NDC 69097-0386-02
- Ambrisentan oral tablet, Mylan (Viatris), 10 mg, bottle, 30 count, NDC 00378-4271-93
- Ambrisentan oral tablet, Mylan (Viatris), 5 mg, bottle, 30 count, NDC 00378-4270-93
- Ambrisentan oral tablet, Sun Pharma, 10 mg, bottle, 30 count, NDC 47335-0237-83
- Ambrisentan oral tablet, Sun Pharma, 5 mg, bottle, 30 count, NDC 47335-0236-83
- Ambrisentan oral tablet, Teva, 5 mg, bottle, 30 count, NDC 00591-2405-30

Estimated Resupply Dates

- Cipla has ambrisentan 10 mg tablets on back order and the company cannot estimate a release date.
- Teva has ambrisentan 10 mg tablets on back order and the company estimates a release date in late-May 2024.
- Zydus has ambrisentan 5 mg and 10 mg tablets on allocation.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.